Read by QxMD icon Read

Therapeutic Delivery

Tsontcho Ianchulev, Robert Weinreb, James C Tsai, Shan Lin, Louis R Pasquale
AIM: Conventional eyedropper-delivered volumes (25-50 µl) exceed the eye's usual tear-film volume (7 µl) and precorneal reservoir capacity, risking overflow and ocular/systemic complications. Piezoelectric high-precision microdosing may circumvent these limitations. Results & methodology: In this masked, nonrandomized, cross-over study, subjects (n = 12) underwent pupil dilation with topical phenylephrine (PE) administered by 32-µl eyedropper (2.5% or 10% formulation) and 8-µl electronic microdosing (10% formulation)...
October 27, 2017: Therapeutic Delivery
Mauricio C De Marzi, Martín Saraceno, Romina Mitarotonda, Marcos Todone, Marisa Fernandez, Emilio L Malchiodi, Martín F Desimone
AIM: To analyze the effect of silica particles on monocyte/macrophage functions. MATERIALS & METHODS: Silica micro- and nanoparticles were obtained by the Stöber method. Their effect on monocyte/macrophage proliferation, activation, membrane integrity and metabolic activity were determined. RESULTS: Silica particles inhibit cell proliferation while 10 nm nanoparticles (NPs) did not affect it. Similarly, silica particles induced strong cell activation...
December 2017: Therapeutic Delivery
Valery A Petrenko
Low efficacy of targeted nanomedicines in biological experiments enforced us to challenge the traditional concept of drug targeting and suggest a paradigm of 'addressed self-navigating drug-delivery vehicles,' in which affinity selection of targeting peptides and vasculature-directed in vivo phage screening is replaced by the migration selection, which explores ability of 'promiscuous' phages and their proteins to migrate through the tumor-surrounding cellular barriers, using a 'hub and spoke' delivery strategy, and penetrate into the tumor affecting the diverse tumor cell population...
December 2017: Therapeutic Delivery
Frank Sainsbury
No abstract text is available yet for this article.
December 2017: Therapeutic Delivery
Allen E Haddrell, David Lewis, Tanya Church, Reinhard Vehring, Darragh Murnane, Jonathan P Reid
Aerosols are dynamic systems, responding to variations in the surrounding environmental conditions by changing in size, composition and phase. Although, widely used in inhalation therapies, details of the processes occurring on aerosol generation and during inhalation have received little attention. Instead, research has focused on improvements to the formulation of the drug prior to aerosolization and the resulting clinical efficacy of the treatment. Here, we highlight the processes that occur during aerosol generation and inhalation, affecting aerosol disposition when deposited and, potentially, impacting total and regional doses...
December 2017: Therapeutic Delivery
Hemlata Kaurav, Deepak N Kapoor
Most diseases and disorders of the brain require long-term therapy and a constant supply of drugs. Implantable drug-delivery systems provide long-term, sustained drug delivery in the brain. The present review discusses different type of implantable systems such as solid implants, in situ forming implants, in situ forming microparticles, depot formulations, polymeric-lipid implants, sucrose acetate isobutyrate and N-stearoyl L-alanine methyl ester systems for continuous drug delivery into brain for various brain diseases including glioblastomas, medulloblastoma, epilepsy, stroke, schizophrenia and Alzheimer's diseases...
December 2017: Therapeutic Delivery
Medha D Joshi
No abstract text is available yet for this article.
December 2017: Therapeutic Delivery
Louise Rosenmayr-Templeton
No abstract text is available yet for this article.
December 2017: Therapeutic Delivery
Kaushalkumar Dave, Venkata Vamsi Krishna Venuganti
Skin-mediated therapeutic delivery is a potential alternative to traditional drug delivery approaches. However, dermal drug delivery is limited to the molecules with optimal physico-chemical properties. To overcome this barrier for delivering 'nonideal' drug molecules across the skin, different drug carriers and penetration enhancement methods have been investigated. Conventional chemical and physical approaches for dermal drug delivery are limited by their skin irritation potential, complexity of application and poor patient compliance...
December 2017: Therapeutic Delivery
(no author information available yet)
No abstract text is available yet for this article.
December 2017: Therapeutic Delivery
Emine Kahraman, Sevgi Güngör, Yıldız Özsoy
Nanocarriers used for alternative drug-delivery strategies have gained interest due to improved penetration and delivery of drugs into specific regions of the skin in recent years. Dermal drug delivery via polymeric-based nanocarriers (polymeric nanoparticles, micelles, dendrimers) and lipid-based nanocarriers (solid-lipid nanoparticles and nanostructured lipid carriers, vesicular nanocarriers including liposomes, niosomes, transfersomes and ethosomes) has been widely investigated. Although penetration of nanocarriers through the intact skin could be restricted, these carriers are particularly considered as feasible for the treatment of dermatological diseases in which the skin barrier is disrupted and also for follicular delivery of drugs for management of skin disorders such as acne...
November 2017: Therapeutic Delivery
Saikat Mukherjee, Raja Shunmugam
No abstract text is available yet for this article.
November 2017: Therapeutic Delivery
Marcilio Cunha-Filho, Maísa Rp Araújo, Guilherme M Gelfuso, Tais Gratieri
The production process of 3D-printed drugs offers unique advantages such as the possibility of individualizing the drug therapy and easily associating different drugs and release technologies in the same pharmaceutical unit. Fused deposition modeling, a 3D printing technique, seems especially interesting for pharmaceutical applications, due to its low cost, precise and reproducible control of the printed structures, and versatility for industrial and laboratory scale. This technique combined with another technology already adapted for the pharmaceutical industry, the hot melt extrusion, is able to incorporate various mechanisms of modified drug release...
November 2017: Therapeutic Delivery
Takashi Nakamura, Hideyoshi Harashima
Immune checkpoint therapy represents a new, revolutionary type of cancer therapy, but emerging evidence indicates that only a minority of patients will benefit from it. The issue of how to improve and widen the clinical response is a pivotal issue, and combining other types of therapy with immune checkpoint inhibitors is currently under development. A nanotechnology-based drug-delivery system (nano DDS) could be an important contribution to the development of an effective combination therapy. In this document, we review recent findings in the field of tumor immunology, which provide a strategy for an efficient combination therapy, and discuss nano DDS that are associated with cancer immunotherapy and nano DDS strategies based on the immune status in tumor microenvironments...
November 2017: Therapeutic Delivery
Mohammad A Obeid, Mohammed M Al Qaraghuli, Manal Alsaadi, Abdullah R Alzahrani, Kanidta Niwasabutra, Valerie A Ferro
Due to the increasing problem of drug resistance, new and improved medicines are required. Natural products and biotherapeutics offer a vast resource for new drugs; however, challenges, including the cost and time taken for traditional drug discovery processes and the subsequent lack of investment from the pharmaceutical industry, are associated with these areas. New techniques are producing compounds with appropriate activity at a faster rate. While the formulation of these combined with drug-delivery systems offers a promising approach for expanding the drug developments available to modern medicine...
November 2017: Therapeutic Delivery
Ketki Bhise, Samaresh Sau, Hashem Alsaab, Sushil Kumar Kashaw, Rakesh Kumar Tekade, Arun K Iyer
Multifunctional nanoparticles (NPs), composed of organic and inorganic materials, have been explored as promising drug-delivery vehicles for cancer diagnosis and therapy. The success of nanosystems has been attributed to its smaller size, biocompatibility, selective tumor accumulation and reduced toxicity. The relationship among numbers of molecules in payload, NP diameter and encapsulation efficacy have crucial role in clinical translation. Advancement of bioengineering, and systematic fine-tuning of functional components to NPs have diversified their optical and theranostic properties...
November 2017: Therapeutic Delivery
Pascale Gauthier
No abstract text is available yet for this article.
November 2017: Therapeutic Delivery
Elaine Harris
The present industry update covers the period 1-31 July 2017. Information was sourced primarily from company press releases, regulatory and patent agencies, scientific literature and various news websites. There was positive approval news this month for GlaxoSmithKline for its new self-injecting treatment for systemic lupus erythematosus but less positive news for Ocular Therapeutix, a new drug application for its treatment for postoperative ocular pain, DEXTENZA™ was rejected for a second time. Endo Pharmaceuticals agreed to withdraw its opioid formulation Opana(®)Er due to abuse concerns...
November 2017: Therapeutic Delivery
Sarinj Fattah, David J Brayden
A 14 amino acid cystin bridge containing neuropeptide was discovered in 1973 and designated as growth hormone-inhibiting hormone, in other words, somatostatin. Its discovery led to the synthesis of three analogs which were licensed for the treatment of acromegaly: octreotide, lanreotide and pasireotide. Somatostatin analogs are currently approved only as either subcutaneous or intramuscular long-acting injections. We examine the challenges that must be overcome to create oral formulations of somatostatin analogs and examine selected clinical trial data...
October 2017: Therapeutic Delivery
Armin Mooranian, Rebecca Negrulj, Ryu Takechi, Emma Jamieson, Grant Morahan, Hani Al-Salami
AIM: A semisynthetic primary bile acid (PBA) has exerted hypoglycemic effects in Type 1 diabetic animals, which were hypothesized to be due to its anti-inflammatory and cellular glucose-regulatory effects. Thus, the research purpose aimed to examine antidiabetic effects of a PBA, in terms of cellular inflammation and survival and insulin release, in the context of supporting β-cell delivery and Type 1 diabetic treatment. MATERIALS & METHODS: 10 formulations were prepared, five without PBA (control) and five with PBA (test)...
October 2017: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"